Sign In
Buy MBIO
$0.741
-0.0201 (-2.64%)
At Close: Jun 03, 2026
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
12:00am, Thursday, 12'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106
01:00pm, Tuesday, 18'th Feb 2020
Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematolo
Mustang Bio to Present at the Phacilitate Leaders World & World Stem Cell Summit 2020
01:30pm, Wednesday, 22'nd Jan 2020
NEW YORK, Jan. 22, 2020 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.
Mustang Bio, Inc. (MBIO) Upgraded to Buy: What Does It Mean for the Stock?
05:00pm, Friday, 27'th Dec 2019
Mustang Bio, Inc. (MBIO) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Hedge Funds Are Done Buying Mustang Bio, Inc. (MBIO)
07:59pm, Friday, 20'th Dec 2019
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towar
MB-107 preceded by low-dose busulfan conditioning continues to be well tolerated and results in development of functional immune system in newly diagnosed infants with XSCID.
Mustang Bio to Participate in the Evercore ISI 2nd Annual HealthCONx Conference
01:30pm, Monday, 02'nd Dec 2019
NEW YORK, Dec. 02, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.
Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
12:30pm, Tuesday, 12'th Nov 2019
NEW YORK, Nov. 12, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.
St. Jude Children’s Research Hospital and the National Institutes of Health to present updated MB-107 clinical data for the treatment of X-linked severe combined.
Avalon Globocare (AVCO) Stock: The Wolf of Wall Street?
05:54pm, Friday, 25'th Jan 2019
Low-priced biotech stocks are often targets of pump-and-dump manipulation scams or other activity designed to make money for a select few, not you (think
Cabaletta Bio Closes $50M Series B Financing | FinSMEs
05:54pm, Wednesday, 09'th Jan 2019
Cabaletta Bio, a biotech company focused on the development of T cell therapies for B cell-mediated autoimmune diseases, closed a $50m Series B financing
An Introduction to Cancer Immunotherapy Treatments
09:35pm, Wednesday, 27'th Dec 2017
Of all the things that your doctor could tell you that might be a cause for alarm, hearing that you have late-stage cancer is probably one of the worst. We've all heard people talk about a 'cure for c
